Adults 18 to 50, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Accuracy of Noninvasive Hemoglobin Sensor by Arms CalculationPrimary· 1-5 hours
Accuracy will be determined by comparing the noninvasive hemoglobin measurement of the pulse oximeter to the hemoglobin value obtained from a blood sample and calculating the arithmetic root mean square (Arms) error value. In order to obtain the Arms value, the blood sample hemoglobin value is subtracted from the pulse oximeter hemoglobin value for a number of samples, the average of this difference is computed as the bias. The standard deviation of the differences is computed as the precision. The square root of the sum of the squares of bias and precision is computed as the Arms Error value.
Group
Value
95% CI
Test Subject
1.13
Adverse events — posted to ClinicalTrials.gov
Time frame: 5 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Test Subject
Serious: 0/93 (0%)
Deaths: 0/93
Other adverse events (6 terms — click to expand)
Reaction
System
Test Subject
Swelling due to IV catheter site infiltration
Injury, poisoning and procedural complications
—
Bruising and swelling at arterial site
Injury, poisoning and procedural complications
—
Vasovagal episode during arterial line placement
Injury, poisoning and procedural complications
—
Numbness secondary to local anesthetic infiltration
In this study, the concentration of hemoglobin within the subject's blood will be reduced in a controlled manner by administering fluids intravenously. The accuracy of a noninvasive hemoglobin sensor will be assessed by comparison to hemoglobin measurements from a laboratory analyzer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06707207 — Predicting Future Errors During Skill Performance
· recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
· Phase 1
· recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease.
· NA
· recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects
· NA
· recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity
· Phase 1, PHASE2
· recruiting
Other Masimo Corporation trials
Trials by the same sponsor.
NCT07223177 — Philips FAST SpO2 Technology With Masimo Sensors for SpO2 Monitoring in the Neonatal, Infant, and Pediatric Populations
· NA
· recruiting
NCT07223164 — Validation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
· NA
· recruiting
NCT06334055 — Validation Study of Mean Arterial Pressure (MAP) Parameter of Masimo INVSENSOR00073
· NA
· completed
NCT06432881 — Investigation of Skin Pigmentation Effect on Performance of Masimo Pulse Oximetry (INSPIRE)
· NA
· recruiting
NCT06148623 — Clinical Performance Testing of Philips FAST SpO2 With Masimo Pulse Oximetry Sensors Across Skin Pigmentation
· NA
· completed
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Masimo Corporation
Last refreshed: 20 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03677375.